FIG. 1





SCREENING PHASE
TITRATION PHASE
STABLE DOSE PHASE
DOUBLE-BLIND WITHDRAWAL PHASE
SAFETY FOLLOW-UP
UP TO 28 DAYS
2 WEEKS
START AT 75 mg, TITRATE UP TO 150 OR 300 mg
2 WEEKS
RANDOMIZATION (BASELINE)
JZP-110 (N=61) (75, 150, OR 300 mg/DAY)
PLACEBO (N=61)
2 WEEKS
DAY -31 TO -3 -1 3 6 9 12 15±2 29±3 43±3 57±3
END OF WEEK 2 4 6 8

FIG. 2


SCREENED SUBJECTS
(N = 402)
228 SCREENING FAILURES
ENROLLED INTO TITRATION PHASE
(SAFETY POPULATION; N=174)
17 DISCONTINUATIONS IN TITRATION PHASE
ENTERED STABLE DOSE PHASE
(N = 157)
9 DISCONTINUATIONS IN STABLE DOSE PHASE
COMPLETED STABLE DOSE PHASE
(N = 148)
21 DID NOT MEET CRITERIA FOR RANDOMIZATION
5 WITHDRAWALS FOR OTHER REASONS
RANDOMIZED TO DOUBLE-BLIND
WITHDRAWAL
(PLACEBO N = 62; JZP-110 N = 60)
MODIFIED INTENT-TO-TREAT
POPULATION
(N = 122)

FIGS. 3A-3B


Placebo (n = 62)
JZP-110 (n = 60)
A) Maintenance of Wakefulness Test
Mean (SD) MWT Sleep Latency, Minutes
50
40
30
20
10
0
Baseline
Week 4
Week 6
13.1
12.3
31.7
29.0
29.7
17.6
B) Epworth Sleepiness Scale
Mean (SD) ESS Score
18
16
14
12
10
8
6
4
2
0
16.0
15.3
6.4
5.9
10.8
6.4

FIGS. 4A-4B




Placebo (n = 62)
JZP-110 (n = 60)
*P < 0.0001 vs placebo
A) MWT
LS Mean (SE) Change From Week 4 to Week 6, Minutes
2
0
-2
-4
-6
-8
-10
-12
-14
-1.6
*
-12.1
B) ESS Score
LS Mean (SE) Change From Week 4 to Week 6
6
5
4
3
2
1
0
-1
-2
4.5
-0.1
*

FIG. 5


Placebo (n = 62)
IZP-110 (n = 60)
*p < 0.0001 vs placebo
Percentage of Patients Reported Worse at Week 6
80%
60%
40%
20%
0%
50.0%
*
20.0%
59.0%
*
21.7%
PGI-C
CGI-C



LS Mean (SE) Change From Baseline
0
1
2
3
4
*P < 0.05 and †P < 0.0001 vs placebo
1.7
2.0
2.5
*
3.0
†
3.2
Placebo (n = 114)
JZP-110 37.5 mg (n = 56)
JZP-110 75 mg (n = 58)
JZP-110 150 mg (n = 116)
JZP-110 300 mg (n = 115)

FIG. 6

FIG. 7



*P<0.05 AND †P<0.001 VS PLACEBO
ABSENTEEISM
PERCENT TIME MISSED IN PAST WEEK
BETTER
WORSE
N=69 30 36 78 80 67 26 35 76 65
BASELINE
WEEK 12
PLACEBO
JZP-110 37.5 mg
JZP-110 75 mg
JZP-110 150 mg
JZP-110 300 mg
PRESENTEEISM
PERCENT IMPAIRMENT
N=69 32 35 79 78 66 26 35 76 63
ACTIVITY IMPAIRMENT
N=113 56 58 116 115 102 49 53 106 93
OVERALL WORK IMPAIRMENT
N=68 30 35 77 78 66 26 35 76 63

FIG. 8



PLACEBO (N=114)
JZP-110 37.5 mg (N=56)
JZP-110 75 mg (N=58)
JZP-110 150 mg (N=116)
JZP-110 300 mg (N=115)
*P<0.05 VS PLACEBO
MCID
LS MEAN (SE) CHANGE FROM BASELINE
0
1
2
3
4
5
6
1.4
1.6
2.0
3.5
*
3.3
*
1.1
2.7
2.9
*
3.1
2.1
PHYSICAL COMPONENT SUMMARY
MENTAL COMPONENT SUMMARY

FIG. 9



LS Mean (SE) Change from Baseline
*P < 0.05 vs placebo
MCID
Placebo (n=114)
JZP-110 (mg):
37.5 (n=56)
75 (n=58)
150 (n=116)
300 (n=115)
Physical Functioning
Role Physical
Bodily Pain
General Health
Vitality
Social Functioning
Role Emotional
Mental Health

FIG. 10A




FIG. 10B




FIG. 11



RANDOMIZED (N=239)
PLACEBO (N=60)
JZP-110 75 mg (N=59)
JZP-110 150 mg (N=60)
JZP-110 300 mg (N=60)
TREATED (N=59)
TREATED (N=59)
TREATED (N=59)
TREATED (N=59)
SAFETY POPULATION
DISCONTINUED (N=7[11.9%])
PROTOCOL VIOLATION N=0
ADVERSE EVENT N=1
LACK OF EFFICACY N=1
REQUEST BY SUBJECT N=1
LOST TO FOLLOW-UP N=1
OTHER N=3
DISCONTINUED (N=10[16.9%])
PROTOCOL VIOLATION N=0
ADVERSE EVENT N=2
LACK OF EFFICACY N=4
REQUEST BY SUBJECT N=1
LOST TO FOLLOW-UP N=1
OTHER N=2
DISCONTINUED (N=8[13.6%])
PROTOCOL VIOLATION N=1
ADVERSE EVENT N=3
LACK OF EFFICACY N=1
REQUEST BY SUBJECT N=1
LOST TO FOLLOW-UP N=0
OTHER N=2
DISCONTINUED (N=16[27.1%])
PROTOCOL VIOLATION N=1
ADVERSE EVENT N=5
LACK OF EFFICACY N=6
REQUEST BY SUBJECT N=2
LOST TO FOLLOW-UP N=0
OTHER N=2
COMPLETED (N=52 [88.1%])
COMPLETED (N=49 [83.1%])
COMPLETED (N=51 [86.4%])
COMPLETED (N=43 [72.9%])

FIG. 12



PLACEBO (N=58)
JZP-110 75 mg (N=59)
JZP-110 150 mg (N=55)
JZP-110 300 mg (N=59)
*P<0.05 AND †P<0.0001 VS PLACEBO
LEAST SQUARES MEAN CHANGE FROM BASELINE ± STANDARD ERROR, MINUTES
WEEK
16
13
10
7
4
1
-2
0
1
2
3
4
5
6
7
8
9
10
11
12
13.7†
10.3†
5.6*
1.3
13.1†
9.2†
4.7
2.2
12.3†
9.8†
4.7
2.1

FIG. 13




PLACEBO (N=58)
JZP-110 75 mg (N=59)
JZP-110 150 mg (N=55)
JZP-110 300 mg (N=59)
*P<0.05 AND †P<0.0001 VS PLACEBO
LEAST SQUARES MEAN CHANGE FROM BASELINE ± STANDARD ERROR
WEEK
0
-2
-4
-6
-8
0
1
2
3
4
5
6
7
8
9
10
11
12
-1.6
-2.1
-2.2
-2.7
-3.2
-3.3
-3.4
-3.8*
-5.2*
-5.4†
-5.5*
-5.6†
-6.4†
-6.4†
-6.7†

FIG. 14


PLACEBO (N=58)
JZP-110 75 mg (N=55)
JZP-110 150 mg (N=55)
JZP-110 300 mg (N=59)
*P<0.05 AND †P<0.0001 VS PLACEBO
PERCENTAGE OF PATIENTS
100%
80%
60%
40%
20%
0%
WEEK
1
4
8
12
53.4%
71.2%
84.9%
84.7%
53.4%
71.2%
89.1%
88.1%
44.8%
66.1%
83.6%
88.1%
39.7%
67.8%
78.2%
84.7%